We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.
| Share Name | Share Symbol | Market | Stock Type |
|---|---|---|---|
| Sareum Holdings Plc | SAR | London | Ordinary Share |
| Price Change | Price Change % | Share Price | Last Trade
|
|
|---|---|---|---|---|
| 0.50 | 1.59% | 32.00 | 08:39:19 |
| Open Price | Low Price | High Price | Close Price | Previous Close |
|---|---|---|---|---|
| 31.50 | 31.50 | 32.00 | 32.00 | 31.50 |
| Industry Sector |
|---|
| PHARMACEUTICALS & BIOTECHNOLOGY |
| Top Posts |
|---|
Posted at 10/7/2024 07:08 by criticalthinker1 Cambridge, UK, 10 July 2024 - Sareum Holdings plc (AIM: SAR), a clinical-stage biotechnology company developing next-generation kinase inhibitors for autoimmune disease and cancer, announces certain management team changes.Dr. Tim Mitchell, co-founder and Chief Executive Officer (CEO), will, after twenty years with the Company, transition to the part-time role of Chief Operating Officer (COO). Dr. Mitchell will continue to serve on Sareum's Board of Directors (the "Board"). Dr. Stephen Parker, currently Non-Executive Chairman, will assume the position of Executive Chairman on the Board. The Board currently intends to seek to appoint a new CEO, at the appropriate time, as the Company and its future strategy develops. Additionally, Mr. Clive Birch has been appointed as Senior Independent Director. Very interesting |
Posted at 01/7/2024 07:32 by yzf750 Sareum Holdings plc("Sareum" or the "Company")Positive Data from SDC-1801 Phase 1 Clinical TrialCambridge, UK, 1 July 2024 - Sareum Holdings plc (AIM: SAR), a clinical-stage biotechnology company developing next-generation kinase inhibitors for autoimmune disease and cancer, is pleased to announce positive topline data from its Phase 1a clinical trial of SDC-1801, a dual TYK2/JAK1 kinase inhibitor being developed as a potential new therapeutic for a range of autoimmune diseases.Following the dosing of the final cohort in the Multiple Ascending Dose stage of the trial, and review of the initial data by the Safety Review Committee, the Company reports that:· Blood plasma levels of SDC-1801 significantly in excess of the predicted therapeutic exposure were achieved, with a half-life of between 17 and 20 hours observed, which suggests that once-daily dosing will be possible*· No deaths or serious adverse events due to SDC-1801 were reported· Although data remains blinded, there appear to be no significant changes in blood cell counts or increases in serum creatinine levels, which may be dose limiting side-effects of brepocitinib, currently the most advanced TYK2/JAK1 dual inhibitor *Half-life is an estimation of the time it takes for an initial concentration of SDC-1801 to be reduced by half in the body.The Company expects that further data, unblinded from drug/placebo recipients, including details of any mild or moderate adverse events and biomarkers of TYK2 and/or JAK1 inhibition, will be available in Q3 2024.Dr Tim Mitchell, Chief Executive Officer of Sareum, commented: "We are delighted that the dosing of subjects in the SDC-1801 clinical trial has been completed successfully and without any serious adverse events. We look forward to building a strong data package to advance SDC-1801 to the next stage of its development." Dr John Reader, Chief Scientific Officer of Sareum, added: "The success of this stage of the clinical trial demonstrates that high blood levels of a dual TYK2/JAK1 kinase inhibitor can be achieved without serious side effects. Together with the long half-life observed, we believe this potentially gives SDC-1801 significant advantages over its competitors. We're grateful to the volunteers who participated in this trial, and to the clinical staff who enabled its timely completion."- END - |
Posted at 22/6/2024 22:48 by criticalthinker1 Just go back to the early days and scrutinise their affiliations.Here is a bit re my prior post...not making it easy for those who are not invested proteins that accelerate structure determination using x-ray crystallography. Once the structure is determined, the Company's innovative fragment screening platform is used to identify novel chemical templates designed to interact with the target protein. Sareum then uses its high-throughput medicinal chemistry platform to rapidly optimise these molecules and develop the most promising into potential drug candidates. Sareum aims to successfully deliver drug candidates for licensing to larger pharmaceutical companies at the pre-clinical or early clinical trials stage. This is funded by provision of its specialist drug discovery capabilities to partners in the pharmaceutical and biotechnology industries. Sareum joined the AIM market of the London Stock Exchange in October 2004 and trades under the symbol SAR. For further information, please visit www.sareum.co.uk This information is provided by RNS The company news service from the London Stock Exchange Just dyor ...just saying politely...those goes way back and was always Tim and Charles vision...albeit they happened upon something very unique ...yet others jumped on the bandwagon...yet they realised small molecular deliverance was paramount. It's very interesting when you read into their specific. Hence why I'm here and Thoth was also. Time will tell. What I liked about lse in the early days was freedom of discussion....i just feel that the posters on lse step on egg shells...being just about correct without the ability to say...what about that post re the USA military...the submarine patent...the positive review re a coronavirus...the patents that had to go to China ...mhra throwing us under the 🚌 Ph. Rf...you name it....GSK are sweating their bollards here...snd AZ KNOW IT All best Steadydanny |
Posted at 04/6/2024 20:29 by criticalthinker1 I think Emma is in the queue Wolfie. It's tiring looking in on here and seeing the seriously unbalanced and deranged responses you give.The clue was for all to see last year in a RNS posted by Sareum (below) and since that RNS things have seen a great leap in the progression of 1801 and 1802 will follow and 737 ticking along despite your lies to acknowledge the proof I had it was still progressing. RNS Sareum announces two new granted patents, including first patent specifically for SDC-1801 Cambridge, UK, 26 June 2023 - Sareum Holdings plc (AIM: SAR), a clinical-stage biotechnology company developing next generation kinase inhibitors for autoimmune disease and cancer, today announces that the first patent specifically relating to SDC-1801, its lead TYK2/JAK1 kinase inhibitor, has been granted in China. Further, a patent has been formally granted for SDC-1802 and several analogues in the United States, extending the scope of protection beyond immuno-oncology. Dr John Reader, Sareum's Chief Scientific Officer, commented: "We're delighted to have the first patent granted for SDC-1801, our lead development programme which recently advanced into a Phase 1a clinical trial in Australia. We look forward to being able to strengthen our intellectual property around this asset in other territories in due course." "Separately, we are really pleased to have extended the scope of patent protection for SDC-1802 in the US. Although oncology remains the primary focus of this asset, this bulwarks our intellectual property position and gives us optionality to explore opportunities in other therapeutic areas." SDC-1801 is a dual TYK2/JAK1 kinase inhibitor being developed as a potential new therapeutic for a range of autoimmune diseases with an initial focus on psoriasis, an autoimmune dermatological condition affecting more than 60 million adults worldwide, with a market size for potential treatments estimated to be worth more than US$30 billion. Sareum recently announced that it has begun dosing healthy subjects in a Phase 1a clinical trial for SDC-1801, in Australia. The China National Intellectual Property Administration (CNIPA) has officially issued patent number CN113056456B, safeguarding SDC-1801 and medical applications of it in treating inflammatory or immune disorders. This is the first patent grant issued to Sareum for SDC-1801 in any territory. Patent applications in Europe (EP3864009), the US (US2021387981) and other territories are still under review. SDC-1802 is a TYK2/JAK1 inhibitor being developed for cancer immunotherapy. Sareum continues to work on the translational studies needed to support the development of SDC-1802, defining the optimal cancer application prior to completing toxicology and manufacturing studies. The United States Patent and Trademark Office (USPTO) has formally granted patent number US 11,673,870 B2 specifically covering the treatment of autoimmune disorders with SDC-1802 and several analogues. While Sareum has previously secured international patents providing comprehensive protection for the compound SDC-1802, this patent extends its scope in the US beyond immuno-oncology. Just read that and see where we are now! Look at the various avenues the drugs can be adopted in! Good luck to genuine holders. I'm convinced as I mentioned before PH are trying to play the share price before imminent fantastic update. They are a despicable company. Its very interesting the timing of the trolls appearing. |
Posted at 25/5/2024 20:17 by criticalthinker1 Re 1801 this from 2023..oh how we have come on 4.5. SAR-20347 SAR-20347 is an oral inhibitor of Tyk2 and Jak1 with selectivity over Jak2 and Jak3. Preclinical assays demonstrated that SAR-20347 inhibited IL-12, IL-23 and IFN-α signaling [22]. Both Tyk2 mutant mice and mice treated with SAR-20347 showed significant reduction of IL-6 and IL-17 in imiquimod-induced skin lesions, but only SAR-20347-treated mice presented reduced levels of IL-23, decreased keratinocyte proliferation and improved clinical score [22]. In addition, SAR-20347-treated mice manifested lower IL-17 gene expression compared to Tyk2 mutant mice [22]. In this model, Works et al. demonstrated that SAR-20347 treated mice showed an almost complete loss of IL-22 gene expression in skin lesions, and they postulate that SAR-20347 would impair the ability of Th17 and γδ cells to induce IL-22 [22]. IL-22 is required for development of autoreactive Th17 cells [77,78]. However, not only IL-22 production was impaired, since IL-22 signaling was also affected in vitro in a human colonic cell line, and STAT3 phosphorylation dependent of IL-22 was completely blocked [22]. Blocking both Tyk2 and Jak1 in this study was more effective than inhibition of Tyk2 alone at reducing psoriasis-like disease severity, keratinocyte proliferation, as well as IL-23, IL-17, IL-6, IL-22, and antimicrobial peptide gene expression, and the authors postulate that targeting a combination of Jak1 and Tyk2 using an orally available inhibitor may be a viable approach for treating psoriasis, but currently there are no ongoing or completed clinical trials for SAR-20347 [22]. The bodies in 'control' of certain narratives know full well what Sareum is undertaking. This is going to make Novacyt huge rise look like a blip. 1802 is going to be on the tail end and the results of 1801 will be very significant in its future All best Steadydanny |
Posted at 20/4/2024 21:06 by criticalthinker1 OK! You wrote off 737 but let's skip that point albeit being in development beyond reportable parameters due to geographical loopholes with the contract.So let's discuss the period of time drugs take to get through their progression and their novel ipr. I draw your attention to this from 10 years ago and beg your esteemed knowledgeable response to genuinely respond that the progress despite its incursions has done nothing but progress. Be careful what you say as anything overly exemplary if offering financial advise is a two way street when being derogatory. Psoriasis is a chronic autoimmune disease affecting the skin and characterized by aberrant keratinocyte proliferation and function. Immune cells infiltrate the skin and release proinflammatory cytokines that play important roles in psoriasis. The Th17 network, including IL-23 and IL-22, has recently emerged as a critical component in the pathogenesis of psoriasis. IL-22 and IL-23 signaling is dependent on the JAK family of protein tyrosine kinases, making JAK inhibition an appealing strategy for the treatment of psoriasis. In this study, we report the activity of SAR-20347, a small molecule inhibitor with specificity for JAK1 and tyrosine kinase 2 (TYK2) over other JAK family members. In cellular assays, SAR-20347 dose dependently (1 nM-10 μM) inhibited JAK1- and/or TYK2-dependent signaling from the IL-12/IL-23, IL-22, and IFN-α receptors. In vivo, TYK2 mutant mice or treatment of wild-type mice with SAR-20347 significantly reduced IL-12-induced IFN-γ production and IL-22-dependent serum amyloid A to similar extents, indicating that, in these models, SAR-20347 is probably acting through inhibition of TYK2. In an imiquimod-induced psoriasis model, the administration of SAR-20347 led to a striking decrease in disease pathology, including reduced activation of keratinocytes and proinflammatory cytokine levels compared with both TYK2 mutant mice and wild-type controls. Taken together, these data indicate that targeting both JAK1- and TYK2-mediated cytokine signaling is more effective than TYK2 inhibition alone in reducing psoriasis pathogenesis. You have probably and hopefully worked out I'm setting you up for a fall and a FOI request into your posts that might be deemed a direct example of disparity to the hopeful success of a small bio with direct links to CRUK. That's actually a criminal offence. |
Posted at 07/4/2024 21:24 by peaceandlove Wolf, the rampers are on a different planet to me. Sareum's current market value is correct, £8million based on the following.1) No revenue. 2) Dilution with more on the cards. 3) As you say 737 was turned down by GSK. 4) None of Sareum's products are proven. 5) Phase 1 of the clinical trial is safety only. 6) The MHRA turned Sareum down for a clinical trial in the UK. This is an enormous red flag for me. 7) Board are still taking large salaries as 'working capital'. 8) It almost 20 years since Sareum were listed on AIM. 20 years and the share price 92% down. 9) No license deals even though Sareum's business model is to license pre clinical or early on in the clinical trial. To be frank, Sareum have had 20 years and produced f all. What does that tell you?????? Oh yeah this is the year of rerate, the year of license deals, the year of 1801, the year of 737, the year of revenue. Come on Sar.... 😆🤣 |
Posted at 29/3/2024 07:25 by peaceandlove SOG and co, you're emotionally investing more of your money into Sareum, as opposed to investigating Sareum's market data or other fundamentals. Your instincts are influenced by emotion not evidence that others can see when completing DD of Sareum.You're encouraging others to follow the crowd and make investment decisions based on your ramping. For example, if everyone is buying Sareum, other holders who are already significantly down feel compelled to buy more shares even if it doesn't align with their long-term investment plans. SOG and all you happy clappers, please STOP with the behaviour! You've have never been right. The market cap of Sar is less than £8million get that into your tunnel vision brains! You'll thank me one day! |
Posted at 29/3/2024 07:10 by peaceandlove Good morning! Below is a post on LSE from Meg was Norma on here, before my time, but believes Wolf and I are the same person LOL. She sounds a lot like SOG LOL perhaps they are the same person? 🤔 She is also calling us 'It' how rude. 🤣MegRS300 Posts: 15 Price: 10.75 No Opinion RE: Valuation…28 Mar 2024 21:25 Some things are open to interpretation. I feel, having used it and then converted $ to E, that we’re currently worth somewhere between £86m and £117m. That involves me removing obscure outliers. LOL, she is valuing Sar at these ridiculous values when it's current market cap is less than £8million 🤦🏻 Btw SOG Sareum hasn't gone bust yet because you and the happy clappers keep on investing because you're SO blinded by the science and think a license deal will happen. Not on your Nelly sunshine. I'll tell you why again. The MHRA refused Sareum a Phase 1 CTA (Clinical Trial Authorisation) despite the fact that an external & experienced Consultancy (CRO) had developed the novel capsule technology for them. The MHRA felt that the novel formulation was not a sufficient innovation to expose fit and healthy volunteer-patients to the risks of the trial. By going to the Australian Regulator Authority, Sareum will to use their diminishing financial resources to show that their prototype drug is safe enough to administer to sick patients in the future (Phase 2a and then Phase 2b). As someone else, it's the last throw of the dice. The Clinical Trial at present, phase 1 assesses only the basic safety of the molecule and has nothing to do with whether it will work or not. It can be compared with base camp for the climb to the summit of Everest. Therefore, even with good safety data it means nothing really. Why are LSE continuing to delude themselves with you SOG has being Chief Ramper. PLEASE STOP! In addition to all of this, Sareum will have to further raise funds which means further dilution. More, more money will need to be raised and it'll be shareholders paying for it! So Meg (Norma) and SOG as I said stop ramping and trying to con more people to invest more into a company that clearly has a mountain to climb. The share price is down nearly 85% since January this year, the market has spoken, you both and the other happy clappers are saying disgusting things to encourage innocent people to invest in a company that is a busted flush! SOG, you should know better, grow up FFS. |
Posted at 28/8/2023 21:17 by criticalthinker1 A timely reminder of why I for one am invested in Sareum, and I feel this RNS is pivotal in Sareums future, albeit you will note the time delays, which I hasten to add are NOT Sareums fault. But diligently overcome imo.Everything in this RNS and especially the part re cytokines and superiority to dexamethasone and invivo trials and finally the indication of continuance of looking at trial data re covid 19....I wonder if the shake is over...you can read Tim's follow up to this RNS, but just thought I'd share the nuts and bolts. 01 Jul 21 Sareum Holdings PLC - Covid-19 Research Project Results RNS Number : 7338D Sareum Holdings PLC 01 July 2021 Sareum Holdings PLC ("Sareum" or the "Company") Completed Covid-19 Research Project Delivers Encouraging Results Cambridge, UK, 1 July 2021 - Sareum Holdings plc (AIM: SAR), the specialist drug development company delivering targeted small molecule therapeutics to improve the treatment of cancer and autoimmune diseases, is pleased to announce encouraging top-line results from its UKRI grant funded Covid-19 research project. The aim of this research project was to investigate the effects of SDC-1801, the Company's proprietary TYK2/JAK1 inhibitor, on cytokine signalling after SARS-CoV-2 infection. It was also designed to confirm whether an over-active inflammatory response (known as a 'cytokine storm') via the Interferon Type 1 pathway can be blocked in this disease by SDC-1801. The project has completed on schedule, with the final results confirming the initial encouraging results as noted in the Company's Interim Results, published on 23 April 2021. The results of the project found that SDC-1801 reduced the levels of cytokines associated with Acute Respiratory Distress Syndrome (ARDS) in human lung cells infected with SARS-CoV-2 and demonstrated a profile that was superior to the anti-inflammatory steroid dexamethasone and similar to baricitinib, a JAK1/JAK2 inhibitor. Subsequent completed in-vivo studies support the initial cellular results and indicate: · Strong evidence that expression of Type 1 interferons (IFNa and IFNb) is reduced by SDC-1801 treatment in a dose-responsive manner; and that · Viral loads did not increase after SDC-1801 administration, a potential concern when anti-inflammatory agents are used to dampen down an over-active immune response A secondary objective, the investigation into whether treatment with SDC-1801 in disease models could protect against bacterial pneumonia following SARS-CoV-2 infection was inconclusive, due to technical shortcomings in the disease model. Subject to successful completion of the ongoing preclinical toxicology studies, requisite approvals and financing, the Company aims to commence Phase 1 clinical trials for SDC-1801 in early 2022. The timing and design of the clinical trials for Covid-19 applications will be determined following consultations with experts in the field. I am of the opinion we are in an extremely exciting period of Sareums progression and from what I'm garnering from msm and covid ...the ongoing trial of 1801 and 'potentially' pari passu 1802 is imo worthy of a squeaky chair update when 'allowed' and 'reportable' Those recent Patents will prove very useful 'if' multiple licences are requested. Best regards Steadydanny |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
